Log in

Dova Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:DOVA)

$28.04
+0.04 (+0.14 %)
(As of 11/11/2019)
Today's Range
$28.00
Now: $28.04
$28.19
50-Day Range
$19.68
MA: $27.51
$28.40
52-Week Range
$5.62
Now: $28.04
$28.54
Volume1.49 million shs
Average Volume499,313 shs
Market Capitalization$807.55 million
P/E RatioN/A
Dividend YieldN/A
Beta2.74
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DOVA
CUSIPN/A
Phone919-748-5975

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.35 million
Book Value$2.71 per share

Profitability

Net Income$-72,280,000.00
Net Margins-544.09%

Miscellaneous

Employees115
Market Cap$807.55 million
Next Earnings DateN/A
OptionableOptionable

Receive DOVA News and Ratings via Email

Sign-up to receive the latest news and ratings for DOVA and its competitors with MarketBeat's FREE daily newsletter.


Dova Pharmaceuticals (NASDAQ:DOVA) Frequently Asked Questions

What is Dova Pharmaceuticals' stock symbol?

Dova Pharmaceuticals trades on the NASDAQ under the ticker symbol "DOVA."

How were Dova Pharmaceuticals' earnings last quarter?

Dova Pharmaceuticals Inc (NASDAQ:DOVA) released its earnings results on Tuesday, August, 6th. The company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.03. The company earned $3.52 million during the quarter, compared to analyst estimates of $5.63 million. Dova Pharmaceuticals had a negative return on equity of 101.60% and a negative net margin of 544.09%. View Dova Pharmaceuticals' Earnings History.

What price target have analysts set for DOVA?

6 brokerages have issued twelve-month price targets for Dova Pharmaceuticals' shares. Their forecasts range from $15.00 to $30.00. On average, they anticipate Dova Pharmaceuticals' share price to reach $26.42 in the next year. This suggests that the stock has a possible downside of 5.8%. View Analyst Price Targets for Dova Pharmaceuticals.

What is the consensus analysts' recommendation for Dova Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dova Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Dova Pharmaceuticals.

Has Dova Pharmaceuticals been receiving favorable news coverage?

Media coverage about DOVA stock has trended very negative on Sunday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Dova Pharmaceuticals earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Dova Pharmaceuticals.

Are investors shorting Dova Pharmaceuticals?

Dova Pharmaceuticals saw a drop in short interest in the month of October. As of October 31st, there was short interest totalling 572,700 shares, a drop of 51.9% from the September 30th total of 1,190,000 shares. Based on an average daily volume of 587,400 shares, the short-interest ratio is currently 1.0 days. Approximately 4.4% of the company's stock are sold short. View Dova Pharmaceuticals' Current Options Chain.

Who are some of Dova Pharmaceuticals' key competitors?

What other stocks do shareholders of Dova Pharmaceuticals own?

Who are Dova Pharmaceuticals' key executives?

Dova Pharmaceuticals' management team includes the folowing people:
  • Dr. David S. Zaccardelli, Pres & CEO (Age 54)
  • Mr. Mark W. Hahn, CFO & Sec. (Age 56)
  • Mr. Kevin Laliberte, Sr. VP of Product Devel. (Age 41)
  • Mr. Jason Levine, VP of Marketing
  • Mr. Ilija Zlatar, Head of U.S. Sales

When did Dova Pharmaceuticals IPO?

(DOVA) raised $66 million in an IPO on Thursday, June 29th 2017. The company issued 4,100,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners served as the underwriters for the IPO.

Who are Dova Pharmaceuticals' major shareholders?

Dova Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include GW&K Investment Management LLC (1.15%), Gabelli Funds LLC (0.26%), GABELLI & Co INVESTMENT ADVISERS INC. (0.11%), Tower Research Capital LLC TRC (0.01%) and Meeder Asset Management Inc. (0.00%). Company insiders that own Dova Pharmaceuticals stock include Alex Sapir, David Zaccardelli, Jason Hoitt, Kevin Laliberte, Lee F Md Phd Allen, Life Sciences Maste Perceptive, Mark W Hahn, Paul B Manning, Roger Jeffs and Steven M Goldman. View Institutional Ownership Trends for Dova Pharmaceuticals.

Which institutional investors are buying Dova Pharmaceuticals stock?

DOVA stock was acquired by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, Gabelli Funds LLC, GABELLI & Co INVESTMENT ADVISERS INC., Tower Research Capital LLC TRC and Meeder Asset Management Inc.. Company insiders that have bought Dova Pharmaceuticals stock in the last two years include Alex Sapir, David Zaccardelli, Life Sciences Maste Perceptive, Paul B Manning and Steven M Goldman. View Insider Buying and Selling for Dova Pharmaceuticals.

How do I buy shares of Dova Pharmaceuticals?

Shares of DOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Dova Pharmaceuticals' stock price today?

One share of DOVA stock can currently be purchased for approximately $28.04.

How big of a company is Dova Pharmaceuticals?

Dova Pharmaceuticals has a market capitalization of $807.55 million and generates $10.35 million in revenue each year. The company earns $-72,280,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. Dova Pharmaceuticals employs 115 workers across the globe.View Additional Information About Dova Pharmaceuticals.

What is Dova Pharmaceuticals' official website?

The official website for Dova Pharmaceuticals is http://www.dova.com/.

How can I contact Dova Pharmaceuticals?

Dova Pharmaceuticals' mailing address is 240 Leigh Farm Road Suite 245, Durham NC, 27707. The company can be reached via phone at 919-748-5975 or via email at [email protected]


MarketBeat Community Rating for Dova Pharmaceuticals (NASDAQ DOVA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  201 (Vote Outperform)
Underperform Votes:  200 (Vote Underperform)
Total Votes:  401
MarketBeat's community ratings are surveys of what our community members think about Dova Pharmaceuticals and other stocks. Vote "Outperform" if you believe DOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel